Physician Assistant · Centennial, CO
NPI
1245728203
Since 2018
Specialty
Physician Assistant
Code 363A00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
6801 S Yosemite St
Centennial, CO, 80112
Phone (303) 773-9000
Groups this clinician bills Medicare through
Medicare paid, 2024
$760K
21,141 services
Medicare patients, 2024
179
Average age 64
Drug cost, 2024
$7.1M
364 prescriptions
Company payments, 2025
$1,427
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mary H King was code J1568 (injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg), 6,450 times for 36 patients. In total Mary H King billed 21,141 services in 51 codes, and Medicare paid $760K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-03-28.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 6,450 | 36 | $37.13 | $239K |
| J2357 Injection, omalizumab, 5 mg | Office | 2,071 | 11 | $29.60 | $61K |
| J1556 Injection, immune globulin (bivigam), 500 mg | Office | 2,000 | 11 | $57.99 | $116K |
| 96366 Intravenous Infusion, Hydration | Office | 318 | 56 | $13.99 | $4,450 |
| 95117 Treatment - Miscellaneous | Office | 186 | 19 | $8.26 | $1,536 |
| 96365 Intravenous Infusion, Hydration | Office | 142 | 58 | $43.43 | $6,167 |
| 99213 Office E&M - Established | Office | 110 | 78 | $51.81 | $5,699 |
| 96372 Injection Administration | Office | 110 | 32 | $9.08 | $999 |
| 99214 Office E&M - Established | Office | 78 | 54 | $71.16 | $5,550 |
| 95115 Treatment - Miscellaneous | Office | 77 | 13 | $6.60 | $508 |
| 96375 Injection Administration | Office | 45 | 20 | $10.58 | $476 |
| J7030 Infusion, normal saline solution , 1000 cc | Office | 42 | 12 | $2.08 | $87.36 |
| 96361 Intravenous Infusion, Hydration | Office | 32 | 13 | $8.47 | $271 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 23 | 12 | $0.80 | $18.51 |
| 99204 Office E&M - New | Office | 18 | 18 | $94.24 | $1,696 |
By year: 2022 $647K for 17,604 services; 2023 $611K for 17,353 services; 2024 $760K for 21,141 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mary H King prescribed most often to Medicare patients was Ruconest (C1 Esterase Inhibitor, Recomb), with 42 prescriptions and refills. In total Mary H King wrote 364 Medicare prescriptions that cost $7.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ruconest C1 Esterase Inhibitor, Recomb | 42 | 42 | Under 11 | $3.6M |
| Hydroxychloroquine Sulfate Generic | 29 | 61 | Under 11 | $1,038 |
| Dupixent Syringe Dupilumab | 25 | 25 | Under 11 | $96K |
| Firazyr Icatibant Acetate | 25 | 25 | Under 11 | $1.1M |
| Haegarda C1 Esterase Inhibitor | 24 | 24 | Under 11 | $581K |
| Montelukast Sodium Generic | 23 | 59 | 14 | $140 |
| Orladeyo Berotralstat Hydrochloride | 16 | 16 | Under 11 | $659K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 12 | 12 | Under 11 | $7,739 |
Brand drugs: 212 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mary H King $1,427 ($1,427 in general payments such as food, travel and fees) from 22 companies. The largest payer was Cycle Pharmaceuticals Inc with $249.
| Company | Payments | Amount |
|---|---|---|
| Cycle Pharmaceuticals Inc | 11 | $249 |
| BioCryst US Sales Co., LLC | 15 | $202 |
| Genzyme Corporation SNY | 11 | $196 |
| Pharming Healthcare, Inc. | 4 | $159 |
| Genentech USA, Inc. ROG.SW | 3 | $92.79 |
| CSL Behring CSL.AX | 3 | $64.97 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $53.67 |
| GC Biopharma USA, Inc. 006280.KS | 3 | $48.81 |
| UCB, Inc. UCB.BR | 2 | $47.76 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $40.35 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.